[Click e-Stock] "Voronoi, Growing Expectations for Clinical Results"

On May 13, Daishin Securities analyzed that the value of new drugs VRN07 and VRN11, currently under development by Voronoi, is estimated at 182 billion KRW and 2.5 trillion KRW, respectively. The firm newly presented a 'Buy' investment rating and set a target price of 150,000 KRW.

Lee Heeyoung, a researcher at Daishin Securities, explained, "The first pipeline, VRN07 (EGFR Exon20 ins), was licensed out in 2020 based on excellent preclinical data," adding, "The preclinical results were successfully reproduced in the Phase 1 clinical trial."

She further stated, "Voronoi has consistently demonstrated its drug design capabilities, non-clinical efficacy verification, and clinical reproducibility, thereby increasing market confidence in its pipeline."

Additionally, she emphasized, "VRN11 (EGFR 19del/L858R/C797S) showed meaningful results by presenting initial Phase 1a clinical data at this year's American Association for Cancer Research (AACR), proving safety without side effects and confirming the drug's efficacy, which has heightened expectations for subsequent data."

She said, "This year, we plan to announce results from the high-dose cohort," and predicted, "If positive data regarding efficacy and safety continue, Voronoi will secure meaningful competitiveness in the EGFR second-line treatment market, which has high unmet medical needs."